Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

as designated an orphan medicinal product on October 8, 2009. Upon granting of a Centralized Marketing Authorization and retention of the orphan medicinal product designation, Cinryze would be entitled to a period of 10 years market exclusivity in respect of the approved therapeutic indication. This 10-year market exclusivity period could be extended cumulatively to 12 years when the results of all studies conducted in compliance with an agreed pediatric investigation plan are completed and included in the summary of product characteristics.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze was approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the recommended indication is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  <
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ANDOVER, Massachusetts y LONDRES, August 29, 2015 ... Inteligencia Anatómica para los sistemas ... reproducibles en Ecografía, tiempos de examen rápidos ... se traduce en mayor confianza diagnóstica en el proceso ... Philips  (NYSE: PHG, AEX: PHIA) ha anunciado hoy el ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Pranoprofen Market, ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation ... an inflammatory drug, pranoprofen was later developed into ... the trade name of pranopulin for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... April 3, 2011 Regado Biosciences, Inc., a privately ... active control agents, announced today the primary results of ... lead product, the anticoagulation system REG1, at the i2 ... Annual Scientific Session & Expo in New Orleans, LA. ...
... of the SPIRIT II, III, IV and COMPARE trials presented ... ABT ) market-leading XIENCE V ® Everolimus ... all four trials, two-year results on the safety and efficacy ... and TAXUS ® Express2™ Paclitaxel-Eluting Coronary Stent Systems ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 2Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 3Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... of global cosmeceutical and skin care brands. Mr. Fernandez comes with a ... years working in operations, purchasing and management for some of the nations biggest ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Ill., Jan. 30 SpineMark Corporation,a spinal care ... develop Spine Centers of Excellence, has entered into ... spinal care at,cost effective rates through the first ... the Healthplace Surgery Benefit(TM). As a result,of ...
... Snyder, president of Catholic Charities USA, issued the ... the State Children,s Health Insurance Program (SCHIP), a ... that do not qualify for Medicaid. The House ... on a compromise version of the legislation, which ...
... Jan. 30 Wellesse, manufacturers of new Liquid ... challenges participants to assess their vitamin knowledge for ... a personal nutrition consultation and a year,s supply ... research on Vitamin D dominates the headlines lately, ...
... for menopausal symptoms, FDA says , , FRIDAY, Jan. ... hormones or "bio-identical hormone replacement therapy," and they ... lose weight to preventing senility. , They,re touted ... conventional hormone-replacement therapy. , But the U.S. Food ...
... Co., Inc. (NYSE Alternext: TPI), a manufacturer and ... Chengdu, China,today announced that the Company has begun ... stock repurchase program. These shares will be,retired to ... shares of its,common stock. , ...
... exclusivity on the 500 mg strengthPITTSBURGH, Jan. 30 ... that its subsidiary Mylan Pharmaceuticals Inc. has received final ... for its Abbreviated New Drug Application (ANDA) for Divalproex ... mg. Mylan has been awarded 180 days of marketing ...
Cached Medicine News:Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Catholic Charities USA Praises Congress for Protecting Health Care for Low-income Children 2Health News:Test Your Vitamin D Knowledge: Wellesse Liquid Sunshine Instant Win and Sweepstakes 2Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: